Pharos iBio Co., Ltd. engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of recurrent ovarian cancer; PHI-501 for refractory solid cancer; PHI-301 for the treatment of refractory lung cancer; and PHI-601 for the treatment of menin inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.
Metrics to compare | 388870 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship388870PeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.2x | −4.9x | −0.6x | |
PEG Ratio | −1.55 | 0.02 | 0.00 | |
Price/Book | 11.3x | 3.0x | 2.6x | |
Price / LTM Sales | - | 14.8x | 3.4x | |
Upside (Analyst Target) | - | 0.0% | 44.8% | |
Fair Value Upside | Unlock | 10.6% | 6.6% | Unlock |